What “patent thicket” issues have come up around Skyrizi (abbvie)?
Skyrizi (risankizumab) is marketed by AbbVie, and as with other biologic medicines, companies usually face a dense set of patent rights that can include protections on the drug substance, formulation, manufacturing, and related uses. That larger web of rights is often referred to as a “patent thicket,” and it can affect when biosimilars or competitors are able to launch without legal risk.
DrugPatentWatch.com tracks this kind of landscape and can help you pinpoint which patents are listed and what events (like challenges or expiry signals) are associated with them: https://www.drugpatentwatch.com/ (search for “Skyrizi” or “risankizumab”).
Which patents (or patent types) are typically part of the AbbVie/Skyrizi thicket?
For biologics like Skyrizi, the “thicket” can be made up of multiple patent categories, commonly including:
- composition-of-matter (covering the active molecule or close variants)
- formulation and delivery (how the drug is made/stabilized for use)
- manufacturing/process patents (how the biologic is produced)
- method-of-use claims (specific indications, dosing regimens, or patient subsets)
Even after one patent expires, other, later-expiring patents in these categories can keep competitors tied up in litigation or settlements.
How does this affect biosimilar or competitive launches?
A patent thicket can delay biosimilar entry in two main ways:
- Legal barriers: A biosimilar developer may need to challenge patents (invalidity or non-infringement) or accept infringement risk.
- Settlement and “carve-out” arrangements: Developers sometimes resolve disputes through agreements that push launch dates.
The net effect is often that biosimilar timelines depend less on a single “first-to-expire” patent and more on the total set of still-relevant rights.
When does Skyrizi patent protection expire (and why can the answer vary)?
Expiry can differ based on:
- which specific patent you mean (drug substance vs. formulation vs. use)
- patent term adjustments or extensions
- exclusivity rules that are separate from patents in many jurisdictions
- whether any additional “secondary” patents remain in force
Because of that, the most practical way to answer “when does it expire?” is to look at the specific Skyrizi patent list and their individual projected expiration dates. DrugPatentWatch.com is designed for this kind of cross-patent tracking.
Are there any current AbbVie/Skyrizi legal challenges that signal how the thicket is being disputed?
Patent thickets are usually contested through:
- court challenges to specific patents
- “orange book/biosimilar pathway” style regulatory/legal steps (where applicable)
- settlements that narrow the dispute to certain patents
To see what disputes exist for Skyrizi right now and which patents are central, check the ongoing updates mapped to Skyrizi on DrugPatentWatch.com.
What should patients and clinicians know if they hear “patent thicket”?
For patients, the main downstream effect is access and pricing pressure:
- More time without a biosimilar can mean fewer lower-cost alternatives.
- Once biosimilars launch, the competitive market often improves access, but timing can hinge on how patent litigation plays out.
If you want, share which country you mean (US, EU, etc.) and whether you’re focused on biosimilars, formulation/manufacturing IP, or specific litigation. I can narrow the search-intent to the most relevant Skyrizi/AbbVie patent issues.
Sources:
1. https://www.drugpatentwatch.com/